Results from the PIONEER Program Trials will be presented at 9:45 a.m. Tuesday in N-Hall E (North, Exhibition Level). ADAMeetingNews.org asked study investigator John B. Buse, MD, PhD, to discuss the significance of the PIONEER studies, which were designed to study the safety and efficacy of an oral formulation of the GLP-1 receptor agonist semaglutide.

Read More